Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11)

Mansoor Mirza; Dana Chase; Brian Slomovitz; René DePont Christensen; Zoltan Novak; Destin Black; Lucy Gilbert; Sudarshan Sharma; Giorgio Valabrega; Lisa Landrum; Lars Hanker; Ashley Stuckey; Ingrid Boere; Michael Gold; Sarah Gill; Bradley Monk; Zangdong He; Shadi Stevens; Robert Coleman; Matthew Powell

doi:10.1016/j.ygyno.2023.06.524

Back

Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11)

Journal article

Peer reviewed

Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11)

Mansoor Mirza, Dana Chase, Brian Slomovitz, René DePont Christensen, Zoltan Novak, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa Landrum, …

Gynecologic oncology, Vol.176, pp.S43-S44

09/2023

DOI: https://doi.org/10.1016/j.ygyno.2023.06.524

Metrics

6 Record Views

Details

Title: Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11)
Creators: Mansoor Mirza
Dana Chase
Brian Slomovitz
René DePont Christensen
Zoltan Novak
Destin Black
Lucy Gilbert
Sudarshan Sharma
Giorgio Valabrega
Lisa Landrum
Lars Hanker
Ashley Stuckey
Ingrid Boere
Michael Gold
Sarah Gill
Bradley Monk
Zangdong He
Shadi Stevens
Robert Coleman
Matthew Powell
Publication Details: Gynecologic oncology, Vol.176, pp.S43-S44
Identifiers: 991006041372402656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: a placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) (LBA 11)

Related links

Metrics

Details